Skip to main content
SpringerLink
Log in
Book cover

Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines pp 233–261Cite as

Immune Stimulating Complexes (ISCOMs) and Quil-A Containing Particulate Formulations as Vaccine Delivery Systems

  • Chapter
  • First Online:

Part of the book series: Immunomics Reviews: ((IMMUN,volume 5))

Abstract

Immune stimulating complexes (ISCOMs) belong to the group of particulate vaccine delivery systems. These particles have received considerable attention in the field of vaccine delivery systems, especially for subunit vaccines. ISCOMs have a spherical, open and cage-like structure and a particle size of around 40nm. They contain an adjuvant (Quil A or QS 21) and an antigen incorporated into or associated with their colloidal structure, making ISCOMs particulate antigen delivery systems which allow co-delivery of antigen and adjuvant. In this chapter we initially describe the components, microstructures and preparation methods of ISCOMs followed by their mechanism of immune stimulation and their use as vaccines.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Akerblom L, Nara P, Dunlop N, Putney S, Morein B (1993) HIV experimental vaccines based on the iscom technology using envelope and GAG gene products. Biotechnol Ther 4(3–4):145–161

    PubMed  CAS  Google Scholar 

  2. Andersson C, Sandberg L, Wernérus H, Johansson M, Lövgren-Bengtsson K, Ståhl S (2000) Improved systems for hydrophobic tagging of recombinant immunogens for efficient iscom incorporation. J Immunol Methods 238(1–2):181–193

    Article  PubMed  CAS  Google Scholar 

  3. Bachmann MF, Jennings GT (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10(11):787–796

    Article  PubMed  CAS  Google Scholar 

  4. Barr IG, Mitchell GF (1996) ISCOMs (immunostimulating complexes): the first decade. Immunol Cell Biol 74(1):8–25

    Article  PubMed  CAS  Google Scholar 

  5. Barr IG, Sjölander A, Cox JC (1998) ISCOMs and other saponin based adjuvants. Adv Drug Deliv Rev 32(3):247–271

    Article  PubMed  CAS  Google Scholar 

  6. Behboudi S, Morein B, Rönnberg B (1995) Isolation and quantification of Quillaja saponaria Molina saponins and lipids in iscom-matrix and iscoms. Vaccine 13(17):1690–1696

    Article  PubMed  CAS  Google Scholar 

  7. Brando C, Ware LA, Freyberger H, Kathcart A, Barbosa A, Cayphas S, Demoitie M-A, Mettens P, Heppner DG, Lanar DE (2007) Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A. Infect Immun 75(2):838–845

    Article  PubMed  CAS  Google Scholar 

  8. Copland MJ, Baird MA, Rades T, McKenzie JL, Becker B, Reck F, Tyler PC, Davies NM (2003) Liposomal delivery of antigen to human dendritic cells. Vaccine 21(9–10):883–890

    Article  PubMed  CAS  Google Scholar 

  9. Copland MJ, Rades T, Davies NM (2000) Hydration of lipid films with an aqueous solution of Quil A: a simple method for the preparation of immune-stimulating complexes. Int J Pharm 196(2):135–139

    Article  PubMed  CAS  Google Scholar 

  10. da Fonseca DPAJ, Frerichs J, Singh M, Snippe H, Verheul AFM (2000) Induction of antibody and T-cell responses by immunization with ISCOMS containing the 38-kilodalton protein of Mycobacterium tuberculosis. Vaccine 19(1):122–131

    Article  PubMed  Google Scholar 

  11. Dalsgaard K (1974) Saponin adjuvants. 3. Isolation of a substance from Quillaja saponaria Molina with adjuvant activity in food-and-mouth disease vaccines. Arch Gesamte Virusforsch 44(3):243–254

    Article  PubMed  CAS  Google Scholar 

  12. Dasarai V, Smith C, Zhong J, Scott G, Rawlinson W, Khanna R (2011) Recombinant glycoprotein B vaccine formulation with TLR9 agonist and immune stimulating complex induces specific immunity against multiple strains of cytomegalovirus. J Gen Virol 92:1021–1031

    Article  CAS  Google Scholar 

  13. Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R, Scott AM, Maraskovsky E, McArthur G, MacGregor D, Sturrock S, Tai TY, Green S, Cuthbertson A, Maher D, Miloradovic L, Mitchell SV, Ritter G, Jungbluth AA, Chen Y-T, Gnjatic S, Hoffman EW, Old LJ, Cebon JS (2004) Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans. Proc Natl Acad Sci U S A 101(29):10697–10702

    Article  PubMed  CAS  Google Scholar 

  14. De Gregorio E, D’Oro U, Wack A (2009) Immunology of TLR-independent vaccine adjuvants. Curr Opin Immunol 21(3):339–345

    Article  PubMed  CAS  Google Scholar 

  15. Demana P, Fehske C, White K, Rades T, Hook S (2004) Effect of incorporation of the adjuvant Quil A on structure and immune stimulatory capacity of liposomes. Immunol Cell Biol 82:547–554

    Article  PubMed  CAS  Google Scholar 

  16. Demana PH, Berger B, Vosgerau U, Rades T, Davies NM (2004) A comparison of pseudo-ternary diagrams of aqueous mixtures of Quil A, cholesterol and phospholipid prepared by lipid-film hydration and dialysis. J Pharm Pharmacol 56(5):573–580

    Article  PubMed  CAS  Google Scholar 

  17. Demana PH, Davies NM, Hook S, Rades T (2005) Quil A-lipid powder formulations releasing ISCOMs and related colloidal structures upon hydration. J Control Release 103(1):45–59

    Article  PubMed  CAS  Google Scholar 

  18. Demana PH, Davies NM, Vosgerau U, Rades T (2004) Pseudo-ternary phase diagrams of aqueous mixtures of Quil A, cholesterol and phospholipid prepared by the lipid-film hydration method. Int J Pharm 270(1–2):229–239

    Article  PubMed  CAS  Google Scholar 

  19. Demento SL, Eisenbarth SC, Foellmer HG, Platt C, Caplan MJ, Mark Saltzman W, Mellman I, Ledizet M, Fikrig E, Flavell RA, Fahmy TM (2009) Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 27(23):3013–3021

    Article  PubMed  CAS  Google Scholar 

  20. Duthie MS, Windish HP, Fox CB, Reed SG (2010) Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 239(1):178–196

    Article  Google Scholar 

  21. Ekström J, Hu K-F, Bengtsson KL, Morein B (1999) Iscom and iscom-matrix enhance by intranasal route the IgA responses to OVA and rCTB in local and remote mucosal secretions. Vaccine 17(20–21):2690–2701

    Article  PubMed  Google Scholar 

  22. Ennis FA, Cruz J, Jameson J, Klein M, Burt D, Thipphawong J (1999) Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMs). Virology 259(2):256–261

    Article  PubMed  CAS  Google Scholar 

  23. Evans TG, McElrath MJ, Matthews T, Montefiori D, Weinhold K, Wolff M, Keefer MC, Kallas EG, Corey L, Gorse GJ, Belshe R, Graham BS, Spearman PW, Schwartz D, Mulligan MJ, Goepfert P, Fast P, Berman P, Powell M, Francis D (2001) QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine 19(15–16):2080–2091

    Article  PubMed  CAS  Google Scholar 

  24. Furrie E, Smith RE, Turner MW, Strobel S, Mowat AM (2002) Induction of local innate immune responses and modulation of antigen uptake as mechanisms underlying the mucosal adjuvant properties of immune stimulating complexes (ISCOMS). Vaccine 20(17–18):2254–2262

    Article  PubMed  CAS  Google Scholar 

  25. Glauert AM, Dingle JT, Lucy JA (1962) Action of saponin on biological cell membranes. Nature 196(4858):953–955

    Article  CAS  Google Scholar 

  26. Gordon S, Teichmann E, Young K, Finnie K, Rades T, Hook S (2010) In vitro and in vivo investigation of thermosensitive chitosan hydrogels containing silica nanoparticles for vaccine delivery. Eur J Pharm Sci 41(2):360–368

    Article  PubMed  CAS  Google Scholar 

  27. Gordon S, Young K, Wilson R, Rizwan S, Kemp R, Rades T, Hook S (2010) In vitro and in vivo investigation of thermosensitive chitosan hydrogels containing silica nanoparticles for vaccine delivery. European Journal of Pharmaceutical Sciences 41(2):360–368

    Article  PubMed  CAS  Google Scholar 

  28. Guo S, Kenne L, Lundgren LN, Rönnberg B, Sundquist BG (1998) Triterpenoid saponins from Quillaja saponaria. Phytochemistry 48(1):175–180

    Article  PubMed  CAS  Google Scholar 

  29. Hawkes CA, McLaurin J (2008) Clinical immunotherapy trials in Alzheimer’s disease. Drug Discov Today 5(3):177–183

    Google Scholar 

  30. Higuchi R, Tokimitsu Y, Komori T (1988) An acylated triterpenoid saponin from Quillaja saponaria. Phytochemistry 27(4):1165–1168

    Article  CAS  Google Scholar 

  31. Hoglund S, Dalsgaard K, Lovgren K, Sundquist B, Osterhaus A, Morein B (1989) ISCOMs and immunostimulation with viral antigens. Sub-cellular biochemistry, 1st edn. Plenum Press, New York

    Google Scholar 

  32. Iosef C, Van Nguyen T, K-I J, Bengtsson K, Morein B, Kim Y, Chang K-O, Azevedo MSP, Yuan L, Nielsen P, Saif LJ (2002) Systemic and intestinal antibody secreting cell responses and protection in gnotobiotic pigs immunized orally with attenuated Wa human rotavirus and Wa 2/6-rotavirus-like-particles associated with immunostimulating complexes. Vaccine 20(13–14):1741–1753

    Article  PubMed  CAS  Google Scholar 

  33. ISCONOVA A (2011) AbISCO® adjuvant user guide. http://www.isconova.com. Accessed 23 March 2011

  34. Jacobs C, Duewell P, Heckelsmiller K, Wei J, Bauernfeind F, Ellermeier J, Kisser U, Bauer CA, Dauer M, Eigler A, Maraskovsky E, Endres S, Schnurr M (2010) An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. Int J Cancer 128(4):897–907

    Article  CAS  Google Scholar 

  35. Johansson M, Lövgren-Bengtsson K (1999) Iscoms with different quillaja saponin components differ in their immunomodulating activities. Vaccine 17(22):2894–2900

    Article  PubMed  CAS  Google Scholar 

  36. Johansson M, Ranlund K, Lovgren-Bengtsson K (2000) Impaired immunogenicity of immunostimulating complexes (iscoms) by administration in slow-release formulations. Microbes Infect 2(9):1003–1010

    Article  PubMed  CAS  Google Scholar 

  37. Keefer M, Wolff M, Gorse G, Graham B, Corey L, Clements-Mann M, Verani-Ketter N, Erb S, Smith C, Belshe R, Wagner L, McElrath M, Schwartz D, Fast P (1997) Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 13(14):1163–1177

    Article  PubMed  CAS  Google Scholar 

  38. Kensil C, Patel U, Lennick M, Marciani D (1991) Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol 146(2):431–437

    PubMed  CAS  Google Scholar 

  39. Kensil CR (1996) Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst 13(1–2):1–55

    PubMed  CAS  Google Scholar 

  40. Kersten GFA, Crommelin DJA (1995) Liposomes and ISCOMS as vaccine formulations. Biochim Biophys Acta 1241(2):117–138

    Article  PubMed  Google Scholar 

  41. Kersten GFA, Spiekstra A, Beuvery EC, Crommelin DJA (1991) On the structure of immune-stimulating saponin-lipid complexes (ISCOMs). Biochim Biophys Acta 1062(2):165–171

    Article  PubMed  CAS  Google Scholar 

  42. Kodama S, Hirano T, Noda K, Umemoto S, Suzuki M (2011) Nasal immunization with plasmid DNA encoding P6 protein and immunostimulatory complexes elicits nontypeable Haemophilus influenzae-specific long-term mucosal immune responses in the nasopharynx. Vaccine 29(10):1881–1890

    Article  PubMed  CAS  Google Scholar 

  43. Könnings S, Copland MJ, Davies NM, Rades T (2002) A method for the incorporation of ovalbumin into immune stimulating complexes prepared by the hydration method. Int J Pharm 241(2):385–389

    Article  PubMed  Google Scholar 

  44. Kruit W, Suciu S, Dreno B, Chiarion-Sileni V, Mortier L, Robert C, Maio M, Brichard V, Lehmann F, Keilholz U (2008) Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group. J Clin Oncol 26(suppl 15):A9065

    Google Scholar 

  45. Larsson M, Lövgren K, Morein B (1993) Immunopotentiation of synthetic oligopeptides by chemical conjugation to iscoms. J Immunol Methods 162(2):257–260

    Article  PubMed  CAS  Google Scholar 

  46. Lendemans DG, Egert AM, Hook S, Rades T (2007) Cage-like complexes formed by DOTAP, Quil-A and cholesterol. Int J Pharm 332(1–2):192–195

    Article  PubMed  CAS  Google Scholar 

  47. Lendemans DG, Egert AM, Myschik J, Hook S, Rades T (2006) On the dilution behaviour of immuno-stimulating complexes (ISCOMs). Pharmazie 61(8):689–695

    PubMed  CAS  Google Scholar 

  48. Lendemans DG, Myschik J, Hook S, Rades T (2005) Cationic cage-like complexes formed by DC-cholesterol, Quil-A, and phospholipid. J Pharm Sci 94(8):1794–1807

    Article  PubMed  CAS  Google Scholar 

  49. Lendemans DG, Myschik J, Hook S, Rades T (2005) Immuno-stimulating complexes prepared by ethanol injection. J Pharm Pharmacol 57(6):729–733

    Article  PubMed  CAS  Google Scholar 

  50. Leroux-Roels I, Koutsoukos M, Clement F, Steyaert S, Janssens M, Bourguignon P, Cohen K, Altfeld M, VandepapeliËre P, Pedneault L, McNally L, Leroux-Roels G, Voss G (2010) Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three adjuvant systems. Vaccine 28(43):7016–7024

    Article  PubMed  CAS  Google Scholar 

  51. Li H, Willingham SB, Ting JP-Y, Re F (2008) Cutting edge: inflammasome activation by alum and alum’s adjuvant effect are mediated by NLRP3. J Immunol 181(1):17–21

    PubMed  CAS  Google Scholar 

  52. Liang M, Toth I, Davies NM (2008) A novel method for preparing immune stimulating complexes (ISCOMs) by hydration of freeze-dried lipid matrix. Eur J Pharm Biopharm 68(3):840–845

    PubMed  CAS  Google Scholar 

  53. Lipford GB, Wagner H, Heeg K (1994) Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells. Vaccine 12(1):73–80

    Article  PubMed  CAS  Google Scholar 

  54. Lövgren K, Lindmark J, Pipkorn R, Morein B (1987) Antigenic presentation of small molecules and peptides conjugated to a preformed iscom as carrier. J Immunol Methods 98(1):137–143

    Article  PubMed  Google Scholar 

  55. Lövgren K, Morein B (1988) The requirement of lipids for the formation of immunostimulating complexes (ISCOMs). Biotechnol Appl Biochem 10(2):161–172

    PubMed  Google Scholar 

  56. Madhun AS, Haaheim LR, Nilsen MV, Cox RJ (2009) Intramuscular matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine 27(52):7367–7376

    Article  PubMed  CAS  Google Scholar 

  57. Madsen H, Ifversen P, Madsen F, Brodin B, Hausser I, Nielsen H (2009) In vitro cutaneous application of ISCOMs on human skin enhances delivery of hydrophobic model compounds through the stratum corneum. AAPS J 11(4):728–739

    Article  PubMed  CAS  Google Scholar 

  58. Madsen HB, Arboe-Andersen HM, Rozlosnik N, Madsen F, Ifversen P, Kasimova MR, Nielsen HM (2010) Investigation of the interaction between modified ISCOMs and stratum corneum lipid model systems. Biochim Biophys Acta 1798(9):1779–1789

    Article  PubMed  CAS  Google Scholar 

  59. Maraskovsky E, Sjölander S, Drane DP, Schnurr M, Le TTT, Mateo L, Luft T, Masterman K-A, Tai T-Y, Chen Q, Green S, Sjolander A, Pearse MJ, Lemonnier FA, Chen W, Cebon J, Suhrbier A (2004) NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ T-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin Cancer Res 10(8):2879–2890

    Article  PubMed  CAS  Google Scholar 

  60. Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol Cell 10(2):417–426

    Article  PubMed  CAS  Google Scholar 

  61. Mbow ML, De Gregorio E, Valiante NM, Rappuoli R (2010) New adjuvants for human vaccines. Curr Opin Immunol 22(3):411–416

    Article  PubMed  CAS  Google Scholar 

  62. McBurney WT, Lendemans DG, Myschik J, Hennessy T, Rades T, Hook S (2008) In vivo activity of cationic immune stimulating complexes (PLUSCOMs). Vaccine 26(35):4549–4556

    Article  PubMed  CAS  Google Scholar 

  63. Medzhitov R, Janeway CA (2002) Decoding the patterns of self and nonself by the innate immune system. Science 296(5566):298–300

    Article  PubMed  CAS  Google Scholar 

  64. Morein B, Bengtsson KL (1999) Immunomodulation by Iscoms, immune stimulating complexes. Methods 19(1):94–102

    Article  PubMed  CAS  Google Scholar 

  65. Morein B, Ekström J, Lövgren K (1990) Increased immunogenicity of a non-amphipathic protein (BSA) after inclusion into iscoms. J Immunol Methods 128(2):177–181

    Article  PubMed  CAS  Google Scholar 

  66. Morein B, Lovgren K, Ronnberg B, Sjolander A, Villacres-Eriksson M (1995) Immunostimulating complexes. Clinical potential in vaccine development. Clin Immunother 3(6):461–475

    Article  Google Scholar 

  67. Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A (1984) Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308(5958):457–460

    Article  PubMed  CAS  Google Scholar 

  68. Morgan D (2006) Immunotherapy for Alzheimer’s disease. J Intern Med 269(1):54–63

    Article  CAS  Google Scholar 

  69. Mowat A, Maloy K, Donachie AM (1993) Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. Immunology 80(4):527–534

    PubMed  CAS  Google Scholar 

  70. Myschik J, Eberhardt F, Rades T, Hook S (2008) Immunostimulatory biodegradable implants containing the adjuvant Quil-A. Part I: physicochemical characterisation. J Drug Target 16(3):213–223

    Article  PubMed  CAS  Google Scholar 

  71. Myschik J, Lendemans DG, McBurney WT, Demana PH, Hook S, Rades T (2006) On the preparation, microscopic investigation and application of ISCOMs. Micron 37(8):724–734

    Article  PubMed  CAS  Google Scholar 

  72. Myschik J, Mcburney WT, Hennessy T, Phipps-Green A, Rades T, Hook S (2008) Immunostimulatory biodegradable implants containing the adjuvant Quil-A. Part II: in vivo evaluation. J Drug Target 16(3):224–232

    Article  PubMed  CAS  Google Scholar 

  73. Myschik J, Rades T, Hook S (2009) Advances in lipid-based subunit vaccine formulations. Curr Immunol Rev 5:42–48

    Article  CAS  Google Scholar 

  74. Nicholaou T, Ebert LM, Davis ID, McArthur GA, Jackson H, Dimopoulos N, Tan B, Maraskovsky E, Miloradovic L, Hopkins W, Pan L, Venhaus R, Hoffman EW, Chen W, Cebon J (2009) Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res 15(6):2166–2173

    Article  PubMed  CAS  Google Scholar 

  75. Ockenhouse CF, Angov E, Kester KE, Diggs C, Soisson L, Cummings JF, Stewart AV, Palmer DR, Mahajan B, Krzych U, Tornieporth N, Delchambre M, Vanhandenhove M, Ofori-Anyinam O, Cohen J, Lyon JA, Heppner DG (2006) Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine 24(15):3009–3017

    Article  PubMed  CAS  Google Scholar 

  76. Oliveira-Freitas E, Casas CP, Borja-Cabrera GP, Santos FN, Nico D, Souza LOP, Tinoco LW, da Silva BP, Palatnik M, Parente JP, Palatnik-de-Sousa CB (2006) Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis. Vaccine 24(18):3909–3920

    Article  PubMed  CAS  Google Scholar 

  77. Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, Lang T, Gould J, Dubois M-C, Jongert E, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Lapierre D, Ballou WR, Cohen J, Lemnge MM, Peshu N, Marsh K, Riley EM, von Seidlein L, Bejon P (2011) Efficacy of RTS, S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis 11(2):102–109

    Article  PubMed  CAS  Google Scholar 

  78. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningoencephalitis in a subset of patients with AD after Αβ42 immunization. Neurology 61(1):46–54

    Article  PubMed  CAS  Google Scholar 

  79. Özel M, Hlund S, Gelderblom HR, Morein B (1989) Quaternary structure of the immunostimulating complex (Iscom). J Ultrastruct Mol Struct Res 102(3):240–248

    Article  PubMed  Google Scholar 

  80. Pandey RS, Dixit VK (2009) Evaluation of ISCOM vaccines for mucosal immunization against hepatitis B. J Drug Target 18(4):282–291

    Article  CAS  Google Scholar 

  81. Pfizer Animal Health (2004) Next generation adjuvant system: Key to enhanced protection conferred by BVDV (Types 1 and 2) components of CattleMaster ®GOLD™. Pfizer Animal Health Technical Bulletin, New York

    Google Scholar 

  82. Pham HL, Shaw PN, Davies NM (2006) Preparation of immuno-stimulating complexes (ISCOMs) by ether injection. Int J Pharm 310(1–2):196–202

    Article  PubMed  CAS  Google Scholar 

  83. Radosevic K, Rodriguez A, Mintardjo R, Tax D, Bengtsson KL, Thompson C, Zambon M, Weverling GJ, UytdeHaag F, Goudsmit J (2008) Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: Impact of distinct additional adjuvants. Vaccine 26(29–30):3640–3646

    Article  PubMed  CAS  Google Scholar 

  84. Reid G (1992) Soluble proteins incorporate into ISCOMs after covalent attachment of fatty acid. Vaccine 10(9):597–602

    Article  PubMed  CAS  Google Scholar 

  85. Rhodes J (1996) Covalent chemical events in immune induction: fundamental and therapeutic effects. Immunol Today 17(7):436–441

    Article  PubMed  CAS  Google Scholar 

  86. Rimmelzwaan GF, Siebelink KHJ, Huisman RC, Moss B, Francis MJ, Osterhaus ADME (1994) Removal of the cleavage site of recombinant feline immunodeficiency virus envelope protein facilitates incorporation of the surface glycoprotein in immune-stimulating complexes. J Gen Virol 75(8):2097–2102

    Article  PubMed  CAS  Google Scholar 

  87. Robson NC, Beacock-Sharp H, Donachie AM, Mowat AM (2003) The role of antigen-presenting cells and interleukin-12 in the priming of antigen-specific CD4+ T cells by immune stimulating complexes. Immunology 110:95–104

    Article  PubMed  CAS  Google Scholar 

  88. Rohn TA, Bachmann MF (2010) Vaccines against non-communicable diseases. Curr Opin Immunol 22(3):391–396

    Article  PubMed  CAS  Google Scholar 

  89. Rönnberg B, Fekadu M, Behboudi S, Kenne L, Morein B (1997) Effects of carbohydrate modification of Quillaja saponaria Molina QH-B fraction on adjuvant activity, cholesterol-binding capacity and toxicity. Vaccine 15(17–18):1820–1826

    Article  PubMed  Google Scholar 

  90. Rönnberg B, Fekadu M, Morein B (1995) Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix. Vaccine 13(14):1375–1382

    Article  PubMed  Google Scholar 

  91. Sambhara S, Kurichh A, Miranda R, Tumpey T, Rowe T, Renshaw M, Arpino R, Tamane A, Kandil A, James O, Underdown B, Klein M, Katz J, Burt D (2001) Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol 211(2):143–153

    Article  PubMed  CAS  Google Scholar 

  92. Sanders MT, Brown LE, Deliyannis G, Pearse MJ (2005) ISCOM™-based vaccines: the second decade. Immunol Cell Biol 83(2):119–128

    Article  PubMed  CAS  Google Scholar 

  93. Schnurr M, Orban M, Robson NC, Shin A, Braley H, Airey D, Cebon J, Maraskovsky E, Endres S (2009) ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II. J Immunol 182(3):1253–1259

    PubMed  CAS  Google Scholar 

  94. Segal R, Shatkovsky P, Milo-Goldzweig I (1974) On the mechanism of saponin hemolysis—I: hydrolysis of the glycosidic bond. Biochem Pharmacol 23(5):973–981

    Article  PubMed  CAS  Google Scholar 

  95. Sjölander A, Cox J, Barr I (1998) ISCOMs: an adjuvant with multiple functions. J Leukoc Biol 64(6):713–723

    PubMed  Google Scholar 

  96. Sjölander A, Lovgren K, Stahl S, Aslund L, Hansson M, Nygren PA, Larsson M, Hagstedt M, Wahlin B, Berzins K, Uhlen M, Morein B, Perlmann P (1991) High antibody-responses in rabbits immunized with influenza-virus iscoms containing a repeated sequence of the plasmodium-falciparum antigen pf155/resa. Vaccine 9(6):443–450

    Article  PubMed  Google Scholar 

  97. Sjölander A, van’t Land B, Bengtsson KL (1997) Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. Cell Immunol 177(1):69–76

    Article  PubMed  Google Scholar 

  98. Smith RE, Donachie AM, Grdic D, Lycke N, Mowat AM (1999) Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses. J Immunol 162(9):5536–5546

    PubMed  CAS  Google Scholar 

  99. Soltysik S, Wu J-Y, Recchia J, Wheeler DA, Newman MJ, Coughlin RT, Kensil CR (1995) Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine 13(15):1403–1410

    Article  PubMed  CAS  Google Scholar 

  100. Sundling C, O’Dell S, Douagi I, Forsell MN, Morner A, Lore K, Mascola JR, Wyatt RT, Karlsson Hedestam GB (2010) Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus. J Virol 84(18):9086–9095

    Article  PubMed  CAS  Google Scholar 

  101. Tschopp J, Schroder K (2010) NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 10(3):210–215

    Article  PubMed  CAS  Google Scholar 

  102. Tyagi P, Mirakhur B (2009) MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 10(5):371–374

    Article  PubMed  Google Scholar 

  103. Ubhi K, Masliah E (2011) Recent advances in the development of immunotherapies for tauopathies. Exp Neurol 230(2):157–161. doi:10.1016/j.expneurol.2010.10.007

    Article  PubMed  CAS  Google Scholar 

  104. Vansteenkiste J, Zielinski M, Linder A, Dahabre J, Esteban E, Malinowski W, Jassem J, Passlick B, Lehmann F, Brichard V (2007) Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 25(18S):7554

    Google Scholar 

  105. Villacres-Eriksson M, Bergström-Mollaoglu M, Kåberg H, Lövgren K, Morein B (1993) The induction of cell-associated and secreted IL-1 by iscoms, matrix or micelles in murine splenic cells. Clin Exp Immunol 93(1):120–125

    Article  PubMed  CAS  Google Scholar 

  106. Waite DC, Jacobson EW, Ennis FA, Edelman R, White B, Kammer R, Anderson C, Kensil CR (2001) Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 19(28–29):3957–3967

    Article  PubMed  CAS  Google Scholar 

  107. White K, Rades T, Furneaux R, Kearns P, Toth I, Hook S (2006) Immunogenicity of liposomes containing lipid core peptides and the adjuvant Quil A. Pharm Res 23(7):1473–1481

    Article  PubMed  CAS  Google Scholar 

  108. Williams A, Flavell RA, Eisenbarth SC (2010) The role of NOD-like receptors in shaping adaptive immunity. Curr Opin Immunol 22(1):34–40

    Article  PubMed  CAS  Google Scholar 

  109. Yu H, Jiang X, Shen C, Karunakaran KP, Jiang J, Rosin NL, Brunham RC (2010) Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-γ)/tumor necrosis factor alpha and IFN-γ/interleukin-17 double-positive CD4+ T cells. Infect Immun 78(5):2272–2282

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. New Zealand’s National School of Pharmacy, University of Otago, Dunedin, New Zealand

    S. Hook & T. Rades

Authors
  1. S. Hook
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Rades
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Hook .

Editor information

Editors and Affiliations

  1. Aston Pharmacy School, School of Life and Health Sciences, University of Aston, Aston Triangle, Birmingham, B4 7ET, United Kingdom

    Darren R. Flower

  2. Aston Pharmacy School, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, B4 7ET, United Kingdom

    Yvonne Perrie

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Hook, S., Rades, T. (2013). Immune Stimulating Complexes (ISCOMs) and Quil-A Containing Particulate Formulations as Vaccine Delivery Systems. In: Flower, D., Perrie, Y. (eds) Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines. Immunomics Reviews:, vol 5. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5070-2_12

Download citation

Publish with us

Policies and ethics

Search

Navigation